INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most frequent cancer in children, accounting for approximately 25% of all pediatric cancers.(1) B-progenitor cell (pre-B), the most prevalent form of ALL in children (~80% of cases), arises from an immature lymphoid progenitor cell that acquires genomic lesions leading to malignant transformation.(1, 2) Cytogenetic analyses detect primary gross chromosomal abnormalities in 75% of pre-B ALL cases, allowing further classification into subtypes based on recurrent translocations or aneuploidies. ( 3) The t (12;21) resulting into the ETV6-RUNX1 fusion, and high hyperdiploidy (> 50 chromosomes) each account for approximately 25% of cases. Less frequent translocations include t(9;22), generating the BCR-ABL fusion (2-4% frequency), t(1;19) TCF3-PBX1 (2-6%), and t(4;11) MLL-AF4 (1-2%).(3) Current treatment regimens for childhood ALL rely on risk classification systems incorporating molecular genetic subtype information, and risk-adapted therapies have improved overall survival rates. However, due to dismal cure rates in high-risk groups, relapse, and drug resistance resulting in treatment failure, pre-B ALL remains the leading cause of cancer-related death in children. (1, 4) In addition, over two-thirds of survivors develop chronic or lateoccurring health problems linked to their disease and its treatment. (5, 6) DNA methylation is a frequent epigenetic modification that occurs almost exclusively in the context of cytosine methylation, and is crucially involved in the regulation of gene expression.(7) Promoter hypermethylation of tumor suppressor genes, hypomethylation of oncogenes, and alterations of micro-RNA (miRNA) gene methylation have been recognized to favor cancer development. (7, 8) Although primary genetic lesions are considered important initiating events in leukemogenesis, it is now evident that cooperating epigenetic alterations including DNA methylation modifications contribute significantly to the phenotype of leukemia cells and disease progression. (8) DNA methylation in childhood ALL has been intensively studied and methylation profiles have been used to distinguish ALL from healthy samples, other leukemias, or ALL subtypes. (9-23) Single CpG-site resolution studies focused on analysis of CpG-islands (CGIs), promoter regions, and regions around the transcription start site (TSS), and recent large-scale approaches screening methylation levels of thousands of protein-coding genes associated with these regions found inverse correlation with gene expression in ALL cell lines and primary cells. (9, 14-18, 20, 22-24) However, recent studies in colon cancer and induced pluripotent stem cells identified substantial alterations of DNA methylation to occur outside of CGIs. (25, 26) The ALL methylome assessed earlier might overlook important ALL subtype classifiers and prognostic markers. The aim of our study was to provide a detailed map of childhood pre-B ALL methylation, and to identify novel pre-B ALL subtype-specific methylation markers within and outside the classic CpG regions. We further investigated the downstream effects of DNA methylation alterations to find clues of pathways perturbed in leukemia, and intersected methylome and transcriptome data to identify methylation events affecting putative genes driving leukemogenesis.
MATERIALS AND METHODS

Patient samples
Bone marrow or peripheral blood samples isolated at diagnosis (leukemia material prior to treatment) and remission (matched normal material following treatment, derived 1 month to 2 years after diagnosis) from 46 children diagnosed with pre-B ALL were analyzed in this study ( Table 1 ). All patients were of French-Canadian origin in order to decrease genetic heterogeneity. The tumor material contained high levels of leukemic blasts (Table 1) 
DNA methylation analysis
Genomic DNA (gDNA) was isolated from frozen cell pellets using a genomic DNA purification kit (Gentra Systems) and 500 ng of it was used for bisulfite conversion employing the EZ DNA Methylation Kit (Zymo Research) according to manufacturer's protocols. The modified gDNA was processed as described in the Infinium Assay Methylation Protocol Guide Rev. C (November 2010), and analyzed on Infinium HumanMethylation450 BeadChips (Illumina), measuring DNA methylation at single CpG-site resolution based on genotyping of C/U polymorphisms. As measure of methylation we chose the β-value, ranging from 0 (no methylation at any allele) to 1.0 (complete methylation of both alleles). We classified the methylation status of probes with β < 0. Table S1 ). The methylation data have been deposited in NCBI's Gene Expression Omnibus: GSE38235.
Array methylation validation with the Sequenom Epityper
Array methylation was validated by quantitative analyses of cleavage products of bisulfite-converted DNA by MALDI-TOF MS (28) using gDNA from twelve patients whose material was also analyzed in the array experiment (Table 1) . For PCR, target-specific primer pairs were designed using the EpiDesigner tool (http://www.epidesigner.com) and 50 ng bisulfite converted gDNA was used as input. Duplicates and unreliably detected CpG units having high or low mass were removed from the analysis.
RNA expression analysis
Total RNA of 17 pre-B ALL tumor samples (Table 1 ) was extracted from cell pellets using the mirVana Kit (Life Technologies). Six μg RNA (RNA integrity number > 6) spiked with ERCC RNA Spike-In Controls (Life Technologies) were rRNA-depleted using the RiboMinus Eukaryote kit (Life Technologies), and cDNA libraries were prepared using the SOLiD Total RNA-seq Kit (Life Technologies). Whole-transcriptome paired-end sequencing (50 bp x 35 bp) was performed using the SOLiD 4 System (Life Technologies). RNA expression 8 levels were assessed as normalized FPKM (fragments per kilobase per million sequenced reads) by running Cufflinks in quantification-only mode, using the UCSC RefSeq database (downloaded November 1, 2010) with additional coordinates for the ERCC spike-in control as reference (Table S2) .
RNA expression validation by quantitative real-time RT-PCR (qPCR)
Tumor RNA from the same twelve patients validated for array methylation was used for expression validation by qPCR (primer sequences given in the supplementary material). Firststrand cDNA synthesis was performed using the Verso cDNA Synthesis Kit (Thermo Scientific) with anchored oligo-dT primers according to manufacturer's protocol. qPCR assays were run on the Rotor-Gene 6000 real-time rotary analyzer (Corbett Life Sciences) using the Platinum SYBR Green qPCR SuperMix-UDG (Life Technologies) according to manufacturer's protocol with the following cycling conditions: 4 min at 95°C, 40 cycles × (20 sec at 95°C, 30 sec at 55°C, and 30 sec at 72°C) followed by the dissociation protocol at 72°C. Transcript expression was analyzed in triplicates. 18S and GAPDH were used for normalization.
Statistical data analysis
Data analyses were performed in R version 2.12.2 (29) applying standard functions and the "lattice" and "RColorBrewer" packages. Heat maps were generated with the "heatmap" function, wherein "hclust" was employed to compute the unsupervised clustering analyses with average linkage as method of clustering and one minus the correlation coefficient (Spearman's rho) as dissimilarity structure. WGCNA was performed in R version 2.14.2 by employing the WGCNA R package for weighted correlation network analysis.(30) Default settings were applied 9 and unsigned networks were constructed; the soft-thresholding power was adjusted to 7, the minimum module size set to 30.
Ingenuity pathway analysis (IPA)
IPA (Ingenuity Systems) content version 12402621 was used. We performed core analyses using approach-specific reference datasets, considered direct and indirect relationships, included endogenous chemicals, and set thresholds to a maximum of 35 
RESULTS
Global methylation landscapes
Methylation profiles were measured in 46 pre-B ALL French-Canadian patients (Table 1) on Illumina 450k BeadChips. For each patient, tumor material was isolated at diagnosis and the corresponding normal material at remission. Taking into account the 392,904 autosomal probes on the chip that mapped uniquely to the genome and showed no genetic variation, we observed a Across samples, individual CpG-site methylation variation was low for the majority of probes: in every CpG-site context more than 56.5% (up to 98.9%) of probes displayed a standard deviation (SD) smaller than 0.1 (Table S3 ). However, we observed significant differences between tumor and normal material (Table S3 ). A SD < 0.1 was observed for more than 95.3%
of CpG-sites in every CpG-site context in normal samples, compared to only 73.6% in tumor samples. In contrast, high CpG-site methylation variation (SD > 0.2) was observed for at least 7.4% of the probes when summed in tumor material, and was rarely observed in normal samples.
Despite these differences we note that DNA methylation patterns are tissue specific. (7) The analyzed tumor material consisted mainly of leukemic blasts which resemble lymphoid progenitor cells within the early developmental stages of B-lymphocytes. (2) In contrast, the corresponding normal material was a mixture of untransformed lymphocytes and monocytes. Therefore, some of the detected methylation alterations might arise from differences in tissue origin rather than be true disease associated methylation changes, and the lower cross-sample CpG-site methylation variation in normal samples might be a result of blunted variability in heterogeneous tissues. Also, patients undergo chemotherapy and remission samples might exhibit treatment-biased methylation patterns which outlast the disease. To circumvent these biases we decided to conduct comparisons between tumor samples to identify tumor and subtype specific methylation alterations. We applied the same clustering approach to methylation levels detected in individual CpG-site neighborhoods and gene regions (Table S4 , Figure S2A -P). In all CpG-site contexts we obtained subtype separations similar to those described above: t(12;21) samples formed a separate cluster, and an additional cluster was formed by the HHD samples. Clustering of methylation levels detected on the X-chromosome followed the same separation patterns ( Figure   S2Q (Table S1 ). We tested whether the detected methylation levels displaying highest cross-sample variance allow hierarchical clustering-based subtype separation (Table S4) 
Correlation of DNA methylation and gene expression levels
DNA methylation is involved in the regulation of gene expression. (7) We observed a decrease in median methylation levels for CpG-sites located within 1kb of the TSS ( Figure S4A ).
When we compared methylation levels and gene expression in 17 patient samples whose transcriptomes had been determined by RNA-sequencing (Table 1) , we found inverse correlation between methylation at CpG-sites located within the TSS1500 and gene expression. The unmethylated / methylated ratio of the highest median expression quartile of transcripts is close to nine ( Figure S4B ), whereas for the lowest expression quartile this ratio dips to two ( Figure   S4C ). We quantified the methylation / expression correlation in different CpG-site regions determining Spearman's rank correlation rho for each patient sample ( Figure 1D ). We observed the highest inverse correlations for CpG-sites located within exon 1, and slight but significant positive correlations for the 3'UTR. Further inverse correlations were observed in the TSS1500, (Table S5 and Table S6 Figure 2B ). This module contains 240 probes, 124 of which displaying lower and 116 displaying higher median methylation levels in samples carrying the t(12;21) translocation when compared to the other samples (Table S7A) .
These probes were associated with 133 genes; their annotations are given in Table S8A .
In addition to the clustering-based WGCNA approach we carried out a Mann-Whitney rank sum test to identify significantly altered DNA methylation patterns specific for the t (12;21) subtype. In this analysis we included all probes that passed our filters and compared probe methylation between samples with and without the t(12;21) translocation. We selected significantly differing probes (false discovery rate (FDR) = 5%) with median β-values < 0. hypermethylated probes in the t(12;21) subtype (Table S7B-C), associated with 85 and 75 genes, respectively. Annotations of probe-associated genes are given in Table S8B -C. A common set of 119 probes and 62 genes were identified by both approaches and are highlighted in Table S7A and S8A, respectively. Less than 50% of the differentially methylated CpG-sites are located in CGIs or around the TSS (Figure 2C-D) .
No probes in the brown module were associated with miRNA genes. In the MannWhitney approach, the only identified probe associated with a miRNA, cg19463199, indicated hypomethylation in the TSS1500 of the miRNA-922 gene in addition to its association with KIAA0226. However, miRNA gene methylation-based clustering separated t(12;21) from other subtypes ( Figure 1C ). To look for evidence of differential methylation at miRNA loci we lowered stringency of our probe selection criteria (FDR 10%, Δβ > 0.25) and identified two additional CpG-sites that confirmed hypomethylation of miRNA-922 and five other differentially methylated miRNA loci within the t(12;21) subtype (Table 2) .
To identify methylation alterations that translate into gene expression differences in the t(12;21) subtype, we selected probes located in regions with observed highest absolute median correlation coefficients (Table S5 ; |median ρ| > 0.1) and compared the methylation trend of associated genes with RNA-sequencing derived transcript expression estimates of the available six t(12;21) and eleven other subtype patient samples. Of the 133 probe-associated genes identified by the WGCNA approach, 49 and 43 were classified as uniformly hypo-and hypermethylated, respectively (Table S9A) . Of these, seven hypomethylated genes (IGF2BP1, DSC3, FAM19A1, TMED6, BEST3, SIDT1, OPN3) and one hypermethylated gene (SPSB1) displayed significantly altered expression levels in t(12;21) ( Table 3) . In every case, significant expression alteration inversely correlated with methylation trend. 
Mann-Whitney analysis identified 85 genes as hypo-and 75 genes as hypermethylated specifically in the t(12;21)-subtype, of which 60 hypo-and 52 hypermethylated genes were associated with probes in regions with high absolute correlation (Table S9B-C). 16 hypomethylated genes (IGF2BP1, DSC3, FAM19A1, TMED6, TCFL5, CHL1, EPOR, SOX11,   BEST3, FUCA1, SIDT1, HLA-DPB1, MYH10, CPNE2, NRN1, GRK7 ) and one hypermethylated gene (FBXL15) showed significantly altered transcript expression levels ( Table 3) . In all instances, hypomethylation was associated with increased transcript expression. However, for hypermethylated gene FBXL15 transcript expression was slightly elevated in t(12;21) samples (Table 3) . Of the 17 identified hypomethylated genes, six were jointly identified by both approaches (IGF2BP1, DSC3, FAM19A1, TMED6, BEST3, SIDT1).
Overall, the median expression levels of genes hypermethylated in t(12;21) (β > 0.7) and unmethylated in the other subtypes (β < 0.3) did not differ significantly (p=0.87 for WGCNA, p=0.65 for Mann-Whitney; Figure 2E ). In contrast, we observed significantly increased median transcript expression levels only for hypomethylated genes in t(12;21). This suggests that the unmethylated genes in the other subtypes are expressed at low levels similar to methylated genes.
Pathway analysis of differentially methylated genes in t(12;21)
Ingenuity Pathway Analysis (IPA) was carried out to determine biological and diseaseassociated pathways affected by differential methylation in t(12;21). Genes differentially methylated in regions displaying high absolute correlation between methylation and expression levels were considered (see above). The WGCNA modules contain both hypo-and hypermethylated genes. We carried out a core analysis including all differentially methylated (Table S9A ) and weighted gene hypo-or hypermethylation as transcriptional up-or downregulation, respectively, with all probe-associated genes considered in the WGCNA approach used as reference dataset. "Cell Cycle, Cancer, Gastrointestinal Disease" was identified as the top associated network, followed by "Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking" (Figure S5A -B, Table S10A ).
In the Mann-Whitney approach we generated two gene lists separating hypo-and hypermethylated genes. We carried out IPA for genes of each list separately (Table S9B -C), weighted differential methylation as previously, and used probe-associated genes interrogated in the Mann-Whitney approach as reference dataset. "Cell Cycle, Cell Death, Cancer" was identified as top network associated with hypomethylation ( Figure S5C and Table S10B), and "Cellular Development, Cellular Growth and Proliferation, Hematological System Development and Function" with hypermethylation ( Figure S5D , Table S10C ).
Finally, we investigated networks generated by genes jointly identified in WCGNA and Mann-Whitney approaches (Table S9B-C); the top associated network was "Cell Death, Cell-ToCell Signaling and Interaction, Hematological System Development and Function" ( Figure S5E , Table S10D ).
Validation of t(12;21)-specific CpG-site methylation and gene expression
We employed the Epityper technology and qPCR to validate array-derived CpG-site methylation and RNA-seq-derived gene expression levels, respectively, in twelve previously analyzed patient samples ( 
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CpG-site the Epityper experiment failed. In all other instances, array methylation significantly correlated (median rho = 0.882) with Epityper methylation ( Figure 3A) . Moreover, previously observed significant methylation differences between samples carrying the t(12;21) translocation and other subtypes were confirmed for all interrogated CpG-sites, except for one (of two) FAM19A1-associated site at chr3:68,136,174 and the SPSB1-associated site at chr1:9,300,572 ( Figure 3B ). Failed validation of t(12;21)-specific methylation at these loci might be due to false positive discovery, or, in case of SPSB1, blurred by additional CpG-sites interrogated in the Epityper CpG unit. Since the Epityper technology quantifies CpG-site methylation on up to 600 bp long stretches of template, we investigated methylation of CpG-sites in close proximity to the array interrogated sites. This identified t(12;21)-specific methylation of SPSB1, and multiple novel loci displaying t(12;21)-specific methylation were discovered ( Figure 3B ), further supporting characterized subtype-specific gene methylation patterns.
Due to limited RNA availability transcript expression validation was targeted to a subset of the methylation validated genes (IGF2BP1, DSC3, FAM19A1, TCFL5, SIDT1, TMED6) . For all genes, we observe high inverse correlations between RNA-seq-derived and qPCR-detected transcript expression ( Figure 4A ), and previously observed subtype-specific expression was validated for all except TMED6 ( Figure 4B ).
DISCUSSION
We studied 46 childhood pre-B ALL sample pairs derived at diagnosis (tumor) and after disease remission (normal) from the QcALL cohort. Importantly, we studied primary material as We report for the first time pre-B ALL subtype separation based on the clustering of methylation levels detected in CGI shores or CGI shelves, associated with individual gene regions, or miRNA genes. Unexpectedly, subtype separation efficiencies achieved in these novel regions were similar to the ones obtained previously, indicating that cross-sample methylation level variance specific to pre-B ALL spans a variety of genomic elements.
DNA methylation in CGIs, CGI shores and at gene promoters is associated with gene silencing;(7) we indeed detect strong inverse correlations between methylation and transcript expression levels in these regions. In contrast, intragenic methylation is assumed to positively correlate with gene expression. We employed two methodically distinct approaches, WGCNA and Mann-Whitney, to identify differential probe methylation in the t(12;21)-subtype. We identified a total of 430 unique CpG-sites specifically related to the t(12;21)-subtype, of which 119 were jointly identified by both approaches. None of these CpG-sites have previously been identified to be differentially methylated in pre-B ALL and all these sites might function as novel epigenetic biomarkers specific for the t(12;21) subtype. Their ultimate suitability, however, will have to be confirmed in larger study cohorts. Furthermore, over 50% of these sites are not located in CGIs or around the TSS, indicating that CpG-site regions previously not investigated at single-site resolution might harbor valuable biomarkers for pre-B ALL.
In the Mann-Whitney approach we also identified t(12;21)-specific CpG-sites associated with miRNA genes. The most statistically significant hit in the hypermethylated cohort was miRNA-320a, which was identified in a recent study (35) CpG-sites identified as t(12;21)-specific were associated with 231 genes (62 were jointly identified by both approaches). Of these, the methylation signatures of BMP4, CELSR1, DSC3, and PON2 were previously identified as subtype classifiers for t (12, 21) . (15) 
As the ETV6-RUNX1 fusion gene was identified to directly bind the EPOR promoter (44) we hypothesized that this interaction might be generally coupled to promoter demethylation.
We tested for it but did not detect significant enrichment of hypomethylated genes identified in our approach when comparing to published RUNX1 chromatin-immunoprecipitation (ChIP)-seq data generated in K562 lymphoblasts.(49) However, K562 cells are derived from chronic myelogenous leukemia, and to ultimately clarify this hypothesis fusion protein ChIP-seq in pre-B ALL needs to be carried out.
Both ETV6 and RUNX1 are known regulators of hematopoiesis (33, 50) . IPA analysis identified the functional network "Hematological System Development and Function" to be significantly associated with differential gene methylation in samples carrying the t (12;21) translocation. Other significant associations include "Cancer" and cellular functions deregulated during carcinogenesis, e.g., "Cell Cycle", "Cell Death", and "Cellular Growth and Proliferation".
TNF, a central hub in several of these generated gene networks, is known to be critically involved in these functions.(51) The most significant networks associated with Mann-Whitneyderived hypo-and hypermethylated genes identified TP53 as central hub. TP53 itself is seldom found to be targeted by genetic alterations in ALL, however, components of the TP53 pathway have been shown to be frequently mutated in ALL,(2) and a recent study reported frequent epigenetic inactivation of TP53 pathway genes in ALL (21).
Overall, this study illustrates the power of methylation profiling to classify leukemic subtypes, and to identify subtype-specific methylation biomarkers. However, most methylation changes do not alter gene expression detectably, so differential methylation analysis seems suitable for epigenetic biomarker discovery, but as tool to understand leukemogenesis it needs to be coupled with other genomic data (e.g. RNA-sequencing). We demonstrate that integrative analysis of Table S9 . P-values derived for genes identified in the WGCNA and Mann-Whitney approaches are highlighted in yellow and blue boxes, respectively; significant differences (p < 0.05) are highlighted in bold. 
